Immunoinformatics Design of a Multi-epitope-based Vaccine Against Colorectal Cancer
Authors
Abstract:
Background: Bioinformatic approaches for designing vaccines have become a promising alternative to conventional methods. We herein designed a multi-epitope-based vaccine against colorectal cancer (CRC). Methods: Used peptides in the CRC vaccines were retrieved from databases of PubMed, Web of Science, Google Scholar, and Clinical trials. The adjuvants of Mycobacterial heparin-binding hemagglutinin and pan DR epitope were inserted in the N and C terminus of the vaccine sequence. Physicochemical properties, immunological characterizations, and prediction of the secondary and tertiary structure of the vaccine were evaluated. Linear and conformational B cells were predicted by IEDB. Docking and molecular dynamics simulations were performed between the vaccine and toll-like receptor of 4 (TLR4). In silico cloning and mRNA stability were predicted to evaluate the expression of the vaccine in Escherichia coli (E.Coli). Results: The vaccine contains 368 amino acids constructed from peptides of OGT, FTO, CASP5, CASP8, U2SURP, MED25, FMO5, CEA, and TGFβIIR CRC antigens. The vaccine has a high-quality structure and suitable physicochemical and immunological properties. It has large and accessible B-celll epitopes. Docking and molecular dynamics simulation of the vaccine with TLR4 showed an appropriate and stable interaction between the vaccine and immune receptors. In silico cloning showed the vaccine can transcript and translate in E.Coli as a host. Conclusion: The CRC vaccine is immunogen, non-allergen, and structurally stable. In the next step, the in silico results of this study will verify using in vitro and in vivo studies.
similar resources
Design of a Multi-epitope Peptide Vaccine against SARS-CoV-2 based on Immunoinformatics Data
Background and purpose: In 2019, the world has witnessed the emergence of a virus that caused acute respiratory distress syndrome in human with high mortality rates (approximately 3.7%). So far, no effective treatment has been proven against COVID-19. This study aimed at designing a multi-epitope vaccine combining several T-cell and B-cell epitopes of the SARS-CoV-2. Materials and methods: Bas...
full textDesign of a Novel Recombinant Multi-Epitope Vaccine against Triple-Negative Breast Cancer
Background: Triple-negative breast cancer (TNBC) is determined by the absence of ERBB2, estrogen and progesterone receptors’ expression. Cancer vaccines, as the novel immunotherapy strategies, have emerged as promising tools for treating the advanced stage of TNBC. The aim of this study was to evaluate Carcinoembryonic antigen (CEA), Metadherin (MTDH), and Mucin 1 (MUC-1) proteins as vaccine ...
full textA Novel Multi-Epitope Vaccine For Cross Protection Against Hepatitis C Virus (HCV): An Immunoinformatics Approach
Background: Hepatitis C virus (HCV) causes acute and chronic human hepatitis infections. Due to the high genetic diversity and high rates of mutations in the genetic material so far there is no approved vaccine against HCV. Materials and Methods: The aim of this study was to determination B and T cell conserved epitopes of E1 and E2 proteins from HCV and construction of a chimeric pepti...
full textT-cell epitope vaccine design by immunoinformatics
Vaccination is generally considered to be the most effective method of preventing infectious diseases. All vaccinations work by presenting a foreign antigen to the immune system in order to evoke an immune response. The active agent of a vaccine may be intact but inactivated ('attenuated') forms of the causative pathogens (bacteria or viruses), or purified components of the pathogen that have b...
full textEpitope-based vaccine against influenza.
The currently available vaccines against influenza are viral strain specific and, hence, their efficacy is limited when the circulating strain is not the one included in them. We review herewith some of the more recently developed influenza vaccines and further describe our own data on the design of epitope-based broad-spectrum vaccine for human use. This vaccine is comprised of recombinant fla...
full textIn silico design a multivalent epitope vaccine against SARS-CoV-2 for Iranian populations
Background: Due to high genetic variation in human leukocyte antigen )HLA( alleles, epitope-based vaccines don’t show equal efficacy in different human populations. therefore, we proposed a multi-epitope vaccine against SARS-CoV-2 for Iranian populations. Materials and Methods: For this purpose, the proteins without allergenicity and high antigenicity as well as conservancy level from SARS-CoV...
full textMy Resources
Journal title
volume 10 issue 3
pages 0- 0
publication date 2022-08
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023